Bristol Myers Squibb potenzia le capacità di produzione della terapia CAR T
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Bristol Myers Squibb boosts CAR T therapy manufacturing capabilities by securing in-house viral vector production capabilities in the US.
After agreeing to acquire a US-based manufacturing facility and its operations from Novartis, Bristol Myers Squibb (BMS) adds in-house production of viral vectors to its capabilities.
The facility in Libertyville, Illinois has the resources to produce viral vectors for BMS’s two CAR T-cell therapies, Abecma and Breyanzi. This move will support the expansion of the company’s global cell therapy manufacturing network.
Specifically, additional production capability will enable BMS to “manufacture current and next-generation vector technology, and increase future capacity,” stated Karin Shanahan, Executive Vice President of Global Product Development & Supply at Bristol Myers Squibb.
The new US facility is planned to transition to Bristol Myers Squibb during 2023, subject to applicable closing conditions being fulfilled.
In addition to the facility in Libertyville, Illinois, BMS has three state-of-the-art cell therapy manufacturing facilities in the US. The company also has two additional manufacturing sites in development: one in the US and another in the Netherlands.